Baxter International (BAX)
(Delayed Data from NYSE)
$40.13 USD
-0.10 (-0.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $40.16 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BAX 40.13 -0.10(-0.25%)
Will BAX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAX
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
BAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Reasons to Hold Baxter International (BAX) in Your Portfolio
Other News for BAX
3 Dividend Stocks For 10%+ Annual Returns
ResMed Inc's Meteoric Rise: Unpacking the 12% Surge in Just 3 Months
Nuwellis Announces Pricing of $2.7 Million Public Offering
My Pink Slip Picks: 3 CEOs That Need to Be Fired
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO